News room

May 2009: Major biopharmaceutical deals for genOway in first quarter of 2009

February 2009: genOway introduces StemCellHY, a new production technology

January 2009: genOway announces a 2-year general agreement with the renowned IMM - University of Zurich

January 2009: genOway launches a legal action against Cellectis S.A. and claims several millions euros for compensation



November 2008: Cardiovascular & metabolic disorders in vivo models: genOway's technology platform is selected by IT-DIAB program

October 2008: A new multi-million dollar agreement signed by genOway with a top 10 pharmaceutical company

June 2008: Cre ERT2 mouse catalog is now available to the scientific community

June 2008: Biopharmaceutical companies acknowledge genOway as their preferred provider for genetically modified rodents

April 2008: genOway signs a major master services agreement with the Japanese pharmaceutical leader Eisai Co., Ltd.

March 2008: Master service agreement with Boehringer Ingelheim Pharmaceuticals Inc.



November 2007: New mouse models in the field of metabolic disorders are now available through genOway

October 2007: genOway signs a contract for up to 2 Million USD in intended services with a US-based leading biopharmaceutical firm

October 2007: genOway is celebrating the award of the Nobel Prize in Medicine to the authors of work on genetic modifications in the mouse.

May 2007: genOway has been selected by the German National Genome Research Network to focus on human diseases: NGFN to fund genOway with 1.1 million euro

May 2007: genOway is successfully entering the stock market: Capital raised will accelerate the transgenic company's technological innovation and industrialization process

February 2007: genOway joins the EUGeneHeart, a EU funded research project focused on prevention and therapy of heart failure



September 2006: Agreement concluded on business Tie-up between TRANSGENIC INC JAPAN and genOway

July 2006: Boehringer Ingelheim reinforces its collaboration with genOway for the development of research models

June 2006: genOway announces a general agreement with major Research Institute in Spain: The Center for Applied Medical Research (CIMA)

May 2006: Charles River Laboratories and genOway announce a North American strategic alliance enabling Genetically-Modified Research Models to assist the drug discovery process

March 2006: genOway announces general agreements with major Research Institutes in Oncology: The European Institute of Oncology & the FIRC Institute on Molecular Oncology- Italy

January 2006: genOway announces General Service Agreement with the SFB 575 - Experimental Hepatology at the Heinrich-Heine-Universität Düsseldorf

December 2005 - January 2006: Invitrogen enters into worldwide co-marketing agreement with genOway focused on RNAi services



November 2005: genOway announces General Service Agreements with the "Max-Planck-Institute for Experimental Medicine" and the "Johann-Wolfgang-Goethe University Frankfurt"

October 2005: genOway takes over transgenic commercial activities of IngenKO Pty Ltd (Australia)

September 2005: 6th Trans-Tech-Meeting genOway prize was awarded to Andras NAGY

June 2005: genOway Germany joins European program to establish new gene therapy vectors

May 2005: genOway Germany announce a 45 % Reduction in Development Time of Genetically Modified Research Models

March 2005: genOway acquires worldwide ddRNAi license from Benitec

February 2005: University College London and genOway announce a general agreement

January 2005: genOway acquires the German transgenic company Murinus



November 2004: genOway and Charles River Laboratories Announce European Collaboration

September 2004: genOway announces collaboration in rat model development with Pfizer

September 2004: genOway raises €4 Million in private equity

September 2004: genOway and the Hubrecht Laboratory announce collaboration in the field of mouse transgenesis

June 2004: genOway announces a general agreement with King's College London

May 2004: genOway announces cooperation in rat model development with ALTANA Pharma

May 2004: genOway receives 1 M € funding for genetically-modified rats

March 2004: Rat models for improving predictability in biopharmaceutical drug research Label EUREKA 3085 - RATMOD



December 2003: Bayer Healthcare AG and genOway announce an agreement in the field of genetically modified mouse models

October 2003: genOway has received the "most innovative biotechnology company award"

September 2003: world's first cloned rats from genOway and INRA

April 2003: genOway raises € 3.3 million in private equity



November 2002: Gene targeting in the rat: genOway S.A. AND CopyRat Pty Ltd. announce significant new R&D partnership

April 2002: Servier and genOway enter collaboration in the field of gene validation



December 2001: genOway succeeds with first cloned rat embryo

September 2001: Cellectis and genOway sign a licensing agreement for the use of homologous recombination

February 2001: SYN X and genOway sign proteomics and genomic strategic alliance

Transgenics (rat and mouse gene modification): knockout mouse (KO mouse), knock in mice (KI mice) and transgenic mouse
genOway, service provider in transgenesis for customized genetically modified mice and rats: gene overexpression, gene knockdown, gene knockout, etc.
| Site map | Legal Notice | © genOway 2006 |